PTHS
$20.74-2.23 (-9.69%)
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
Recent News
Pelthos Therapeutics Inc (PTHS) Q4 2025 Earnings Call Highlights: Prescription Surge and ...
Pelthos Therapeutics Inc (PTHS) reports a 129% increase in prescriptions and strategic acquisitions, bolstering its financial position and setting the stage for future growth.
Pelthos Therapeutics Q4 Earnings Call Highlights
Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported fourth-quarter and full-year 2025 results on its earnings call, highlighting rapid early demand for its lead product ZELSUVMI, two newly acquired FDA-approved dermatology products, and financing transactions that management said strengthened the bala
Pelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue Estimates
Pelthos Therapeutics Inc. (PTHS) delivered earnings and revenue surprises of +28.35% and +3.78%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Sector Update: Health Care Stocks Rise Late Afternoon
Health care stocks advanced late Thursday afternoon, with the NYSE Health Care Index rising 0.9% and